<DOC>
	<DOCNO>NCT00004248</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Interleukin-2 may stimulate person 's white blood cell kill liver cancer cell . PURPOSE : Phase II trial study effectiveness doxorubicin interleukin- 2 treat patient liver cancer remove surgery .</brief_summary>
	<brief_title>Doxorubicin Interleukin-2 Treating Patients With Liver Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate immunological response doxorubicin protract recombinant interleukin-2 term alteration hepatocellular carcinoma specific cytotoxic T cell detectable peripheral blood patient unresectable hepatocellular carcinoma . II . Determine toxicity treatment regimen patient population . III . Determine tumor response regimen term change alpha fetoprotein tumor size measure CT scan patient . IV . Determine progression free survival overall survival patient population treat regimen . V. Determine correlation immunological response , tumor response , progression free survival overall survival patient . OUTLINE : Patients receive doxorubicin IV 3-5 minute day 1 recombinant interleukin-2 ( IL-2 ) IV continuously begin day 5 continue day 57 . Patients achieve partial complete clinical response regardless immunological response patient stable disease immunological response continue IL-2 therapy continuously day 92 . Patients stable disease immunological response receive additional dose doxorubicin day 57 continue IL-2 day 92 . Patients clinically eligible progressive disease immunological response continue IL-2 therapy . Patients follow 2 week monthly thereafter . PROJECTED ACCRUAL : A total 24-30 patient accrue study within approximately 3 year .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove hepatocellular carcinoma OR Elevation alpha fetoprotein ( AFP ) ( great 400 ng/mL ) presence space occupy lesion liver know chronic liver disease Lesion must easily biopsied Unresectable disease Bidimensionally measurable disease radiography OR Evaluable disease elevate AFP Okuda stage I disease Tumor size le 50 % liver No ascites Albumin great 3 g/dL Bilirubin le 2 mg/dL OR Okuda stage II disease Bilirubin stage I If ascites present , albumin must great 3 g/dL PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Hemoglobin least 9.0 g/dL Neutrophil count least 1,500/mm3 Platelet count least 80,000/mm3 Hepatic : See Disease Characteristics SGOT/SGPT great 4 time upper limit normal Any cause underlie liver disease include hepatitis B C allow Renal : Creatinine great 2.0 mg/dL Cardiovascular : No poor cardiac function No myocardial infarction within past 6 month No poorly control arrhythmia No congestive heart failure LVEF least 45 % MUGA Other : No active hepatic encephalopathy No active malignancy except curatively treat nonmelanoma skin cancer carcinoma situ cervix HIV negative No immunodeficiency Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 6 week since prior immunotherapy , include interferon Chemotherapy : No prior systemic intra arterial doxorubicin At least 6 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics Other : At least 4 week since prior investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
</DOC>